AMNEAL PHARMACEUTICALS, INC. AMRX

19.77 (0.04) (0.20%) as of 25 Sep
Market cap
$6.3B
P/E
39.5×
Growth Flags show if company had growth for consecutive years

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Revenue
1,018.23 1,033.65 1,662.99 1,626.37 1,992.52 2,093.67 2,212.30 2,393.61 2,793.96 3,018.76
Revenue Growth
18.33% 1.52% 60.88% (2.20%) 22.51% 5.08% 5.67% 8.20% 16.73% 8.05%
Cost of Revenue
420.77 507.48 946.59 1,273.38 1,364.13 1,324.70 1,427.60 1,573.04 1,773.52 1,905.45
Gross Profit
597.46 526.18 716.40 353.00 628.39 768.97 784.71 820.56 1,020.44 1,113.31
R&D Expenses
179.02 171.42 194.19 188.05 179.93 201.85 195.69 163.95 190.71 186.18
SG&A Expenses
118.76 109.05 227.85 289.60 326.73 365.50 399.70 429.68 476.44 526.83
Operating Income
284.88 245.10 (19.67) (248.68) 91.15 152.72 (94.93) 204.37 249.33 394.10
Non-operating Income/Expense
(70.06) (73.78) (183.05) 28.44 (126.93) (121.35) (153.20) (244.64) (304.34) (254.89)
Non-operating Interest Expenses
55.28 71.06 143.57 168.21 146.00 136.33 158.38 210.63 258.60 241.09
EBT
214.82 171.32 (202.72) (220.24) (35.78) 31.37 (248.13) (40.27) (55.01) 139.21
Income Tax Provision
5.40 2.00 (1.42) 383.33 (104.36) 11.20 6.66 8.45 18.86 11.28
Income after Tax
209.43 169.33 (201.30) (603.57) 68.58 20.17 (254.79) (48.72) (73.88) 127.93
Dividends (Preferred)
207.38 167.65 (148.81) — 0.00 0.00 0.00 — — —
Non-Controlling Interest
2.05 1.68 (31.58) (241.66) (22.48) 9.55 (124.80) 35.27 43.01 55.88
Net Income Common
0.00 — (20.92) (361.92) 91.06 10.62 (129.99) (83.99) (116.89) 72.06
EPS (Basic)
(6.63) (6.53) (1.58) (2.74) 0.62 0.07 (0.86) (0.48) (0.38) 0.23
EPS (Diluted)
(6.63) (6.53) (1.58) (2.74) 0.61 0.07 (0.86) (0.48) (0.38) 0.22
Shares (Basic, Weighted)
71.00 74.00 127.25 132.11 147.44 148.92 150.94 176.14 308.98 313.37
Shares (Diluted, Weighted)
71.00 74.00 127.25 132.11 148.91 151.82 150.94 176.14 308.98 324.81
Gross Margin
58.68% 50.90% 43.08% 21.70% 31.54% 36.73% 35.47% 34.28% 36.52% 36.88%
EBIT Margin
27.98% 23.71% (1.18%) (15.29%) 4.57% 7.29% (4.29%) 8.54% 8.92% 13.05%
EBT margin
21.10% 16.57% (12.19%) (13.54%) (1.80%) 1.50% (11.22%) (1.68%) (1.97%) 4.61%
Net Profit Margin
0.00% 0.00% (1.26%) (22.25%) 4.57% 0.51% (5.88%) (3.51%) (4.18%) 2.39%
Free Cash Flow Margin
(0.94%) 11.60% 10.73% (5.89%) 15.70% 9.27% (1.15%) 11.55% 7.88% 7.54%
EBITDA
320.95 295.62 134.01 1.42 335.22 395.32 153.84 445.32 514.61 640.10
EBIT
284.88 245.10 (19.67) (248.68) 91.15 152.72 (94.93) 204.37 249.33 394.10
Income from Continuous Operations
209.43 169.33 (201.30) (603.57) 68.58 20.17 (254.79) (48.72) (73.88) 127.93
Consolidated Net Income/Loss
209.43 169.33 (201.30) (603.57) 68.58 20.17 (254.79) (48.72) (73.88) 127.93
EPS (Basic, from Continuous Ops)
— — (1.58) (4.57) 0.47 0.14 (1.69) (0.28) (0.24) 0.41
EPS (Basic, Consolidated)
— — (1.58) (4.57) 0.47 0.14 (1.69) (0.28) (0.24) 0.41
EPS (Diluted, from Cont. Ops)
— — (1.58) (4.57) 0.46 0.13 (1.69) (0.28) (0.24) 0.39
Shares (Diluted, Average)
71.15 71.86 127.25 132.11 148.91 151.82 150.94 176.14 308.98 324.81
EPS (Diluted, Consolidated)
— — (1.58) (4.57) 0.46 0.13 (1.69) (0.28) (0.24) 0.39
EBITDA Margin
31.52% 28.60% 8.06% 0.09% 16.82% 18.88% 6.95% 18.60% 18.42% 21.20%
Operating Cash Flow Margin
11.30% 22.66% 15.05% 0.10% 19.02% 11.55% 2.94% 14.44% 10.56% 11.26%

Fold the line items

In millions of $ except per-share values · columns are period end dates